Literature DB >> 25301630

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

Elza C de Bruin1, Nicholas McGranahan2, Richard Mitter3, Max Salm3, David C Wedge4, Lucy Yates5, Mariam Jamal-Hanjani1, Seema Shafi1, Nirupa Murugaesu1, Andrew J Rowan3, Eva Grönroos3, Madiha A Muhammad1, Stuart Horswell3, Marco Gerlinger3, Ignacio Varela6, David Jones4, John Marshall4, Thierry Voet7, Peter Van Loo7, Doris M Rassl8, Robert C Rintoul8, Sam M Janes9, Siow-Ming Lee10, Martin Forster10, Tanya Ahmad11, David Lawrence11, Mary Falzon11, Arrigo Capitanio11, Timothy T Harkins12, Clarence C Lee12, Warren Tom12, Enock Teefe12, Shann-Ching Chen12, Sharmin Begum3, Adam Rabinowitz3, Benjamin Phillimore3, Bradley Spencer-Dene3, Gordon Stamp3, Zoltan Szallasi13, Nik Matthews3, Aengus Stewart3, Peter Campbell4, Charles Swanton14.   

Abstract

Spatial and temporal dissection of the genomic changes occurring during the evolution of human non-small cell lung cancer (NSCLC) may help elucidate the basis for its dismal prognosis. We sequenced 25 spatially distinct regions from seven operable NSCLCs and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC cytidine deaminase activity. Despite maintained carcinogen exposure, tumors from smokers showed a relative decrease in smoking-related mutations over time, accompanied by an increase in APOBEC-associated mutations. In tumors from former smokers, genome-doubling occurred within a smoking-signature context before subclonal diversification, which suggested that a long period of tumor latency had preceded clinical detection. The regionally separated driver mutations, coupled with the relentless and heterogeneous nature of the genome instability processes, are likely to confound treatment success in NSCLC.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301630      PMCID: PMC4636050          DOI: 10.1126/science.1253462

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  34 in total

1.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient.

Authors:  William Lee; Zhaoshi Jiang; Jinfeng Liu; Peter M Haverty; Yinghui Guan; Jeremy Stinson; Peng Yue; Yan Zhang; Krishna P Pant; Deepali Bhatt; Connie Ha; Stephanie Johnson; Michael I Kennemer; Sankar Mohan; Igor Nazarenko; Colin Watanabe; Andrew B Sparks; David S Shames; Robert Gentleman; Frederic J de Sauvage; Howard Stern; Ajay Pandita; Dennis G Ballinger; Radoje Drmanac; Zora Modrusan; Somasekar Seshagiri; Zemin Zhang
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

2.  Punctuated evolution of prostate cancer genomes.

Authors:  Sylvan C Baca; Davide Prandi; Michael S Lawrence; Juan Miguel Mosquera; Alessandro Romanel; Yotam Drier; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Mahmoud Ghandi; Eliezer Van Allen; Gregory V Kryukov; Andrea Sboner; Jean-Philippe Theurillat; T David Soong; Elizabeth Nickerson; Daniel Auclair; Ashutosh Tewari; Himisha Beltran; Robert C Onofrio; Gunther Boysen; Candace Guiducci; Christopher E Barbieri; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Alex H Ramos; Wendy Winckler; Michelle Cipicchio; Kristin Ardlie; Philip W Kantoff; Michael F Berger; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Olivier Elemento; Gad Getz; Francesca Demichelis; Mark A Rubin; Levi A Garraway
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

3.  Allele-specific copy number analysis of tumors.

Authors:  Peter Van Loo; Silje H Nordgard; Ole Christian Lingjærde; Hege G Russnes; Inga H Rye; Wei Sun; Victor J Weigman; Peter Marynen; Anders Zetterberg; Bjørn Naume; Charles M Perou; Anne-Lise Børresen-Dale; Vessela N Kristensen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

Review 4.  On the origin of G --> T transversions in lung cancer.

Authors:  Gerd P Pfeifer; Pierre Hainaut
Journal:  Mutat Res       Date:  2003-05-15       Impact factor: 2.433

5.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

Review 6.  Management of non-small-cell lung cancer: recent developments.

Authors:  Martin Reck; David F Heigener; Tony Mok; Jean-Charles Soria; Klaus F Rabe
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

7.  Chromosomal instability confers intrinsic multidrug resistance.

Authors:  Alvin J X Lee; David Endesfelder; Andrew J Rowan; Axel Walther; Nicolai J Birkbak; P Andrew Futreal; Julian Downward; Zoltan Szallasi; Ian P M Tomlinson; Michael Howell; Maik Kschischo; Charles Swanton
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

8.  A small-cell lung cancer genome with complex signatures of tobacco exposure.

Authors:  Erin D Pleasance; Philip J Stephens; Sarah O'Meara; David J McBride; Alison Meynert; David Jones; Meng-Lay Lin; David Beare; King Wai Lau; Chris Greenman; Ignacio Varela; Serena Nik-Zainal; Helen R Davies; Gonzalo R Ordoñez; Laura J Mudie; Calli Latimer; Sarah Edkins; Lucy Stebbings; Lina Chen; Mingming Jia; Catherine Leroy; John Marshall; Andrew Menzies; Adam Butler; Jon W Teague; Jonathon Mangion; Yongming A Sun; Stephen F McLaughlin; Heather E Peckham; Eric F Tsung; Gina L Costa; Clarence C Lee; John D Minna; Adi Gazdar; Ewan Birney; Michael D Rhodes; Kevin J McKernan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

Review 9.  The causes and consequences of genetic heterogeneity in cancer evolution.

Authors:  Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution.

Authors:  Sally M Dewhurst; Nicholas McGranahan; Rebecca A Burrell; Andrew J Rowan; Eva Grönroos; David Endesfelder; Tejal Joshi; Dmitri Mouradov; Peter Gibbs; Robyn L Ward; Nicholas J Hawkins; Zoltan Szallasi; Oliver M Sieber; Charles Swanton
Journal:  Cancer Discov       Date:  2014-01-19       Impact factor: 39.397

View more
  457 in total

1.  Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Authors:  J-I Lai; Y-C Lai; Y-C Chen; N-K Wang; J-N Pan; W-S Wang; S-C Chang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

Review 2.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

3.  multiSNV: a probabilistic approach for improving detection of somatic point mutations from multiple related tumour samples.

Authors:  Malvina Josephidou; Andy G Lynch; Simon Tavaré
Journal:  Nucleic Acids Res       Date:  2015-02-26       Impact factor: 16.971

Review 4.  Big Bang Tumor Growth and Clonal Evolution.

Authors:  Ruping Sun; Zheng Hu; Christina Curtis
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 5.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

6.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

7.  ZWINT is the next potential target for lung cancer therapy.

Authors:  Fang Peng; Qiang Li; Shao-Qing Niu; Guo-Ping Shen; Ying Luo; Ming Chen; Yong Bao
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-14       Impact factor: 4.553

Review 8.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

9.  The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization.

Authors:  Markus-Frederik Bohn; Shivender M D Shandilya; Tania V Silvas; Ellen A Nalivaika; Takahide Kouno; Brian A Kelch; Sean P Ryder; Nese Kurt-Yilmaz; Mohan Somasundaran; Celia A Schiffer
Journal:  Structure       Date:  2015-04-23       Impact factor: 5.006

Review 10.  Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.

Authors:  Sumitra Mohan; Francesca Chemi; Ged Brady
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.